

Supplementary table 1 – Individual features per feature set (adapted from the rapid COVID-19 case report form. Removed values due to missing more than 50% of values are underlined.

Premorbid	Clinical presentation	Laboratory / Radiology findings
Age	Bleeding (Haemorrhage)	<u>Adenovirus PCR positive</u>
AIDS / HIV	Days since infection before hospital admission	ALT
Asthma (physician diagnosed)	Diastolic blood pressure	<u>aPTT</u>
Autoimmune and/or inflammatory diseases	<u>Disturbed capillary refill</u>	AST
Chronic cardiac disease, including congenital heart disease (not hypertension)	Heart rate	Bacteria in sputum cultured
Chronic hematologic disease	History of fever	Blood Albumin
Chronic kidney disease	Irregular heart rhythm	Blood cultures positive
Chronic neurological disorder	Respiratory rate	Blood Urea Nitrogen
Chronic pulmonary disease (not asthma)	Seizures	CO-RADS CT thorax score
Diabetes with complications	Shortness of breath (Dyspnea)	<u>Blood Creatinine kinase</u>
Diabetes without complications	Systolic blood pressure	Blood Creatinine value
Gender	Temperature	Blood CRP
Healthcare worker	Oxygen saturation	<u>Blood D-dimer</u>
Hypertension	Oxygen saturation measured on room air	<u>Blood Ferritine</u>
Immunosuppressive medication	Oxygen saturation on oxygen therapy	<u>Blood Fibrinogen</u>
Malignant neoplasm		<u>FiO2 supplied</u>
Microbiology worker		Blood Glucose
Mild liver disease		Blood Haemoglobin
Moderate or severe liver disease		Influenza PCR positive
Number of different medicine patient uses		<u>Blood INR</u>
Regular medicine use at home		<u>Blood Lactate value</u>
Rheumatologic disorder		Blood LDH
Rheumatologic disorder		Other Infectious Respiratory diagnosis confirmed
		PaO2 – Arterial blood gas
		PaO2 – Capillary blood gas
		PaO2 – Venous blood gas
		PaCO2 – blood gas
		PH value – blood gas

		Blood Platelets value
		Blood Potassium
		<u>Blood PT</u>
		SaO2 – Blood gas
		Blood Lymphocyte count
		Blood Neutrophil Count
		Blood Sodium
		Thoracic CT findings
		Blood Total Bilirubin
		Blood Total calcium
		Blood White blood cell count value
		<u>Presence of infiltrates on lung imaging</u>

Supplementary table 2: Hyper-parameters used for optimizing LR or XGB models.

A 50-iteration randomized grid-search was used for both models. The values in square brackets under parameters name are the parameter names as per function in the code.

Classifier	Parameter Name	Parameter Value
XGB	[Learning rate]	[0.1, 0.01, 0.001]
	[Gamma] Minimum loss reduction required to make a further partition on a leaf node of the tree	[0.1, 0.01, 0.001]
	[N estimators]	[100, 200, 300, 500, 700]
	[Subsample] Subsample ratio of the training instances	[0.5, 0.7, 0.9]
	[Colsample by tree] Parameters for subsampling the columns	[0.5, 0.6, 0.7, 0.8]
	[Max depth] Maximum depth of a tree	[2, 4, 6, 8]
	LR	[Solver]
[Penalty] Regularization penalty type		[Elasticnet, L2]
[L1 Ratio] Ratio between L1 and L2 regularization		[0.0, 0.2, 0.4, 0.6, 0.8, 1.0]
[C] Inverse regularization strength		[0.0, 0.001, 0.006, 0.046, 0.359, 2.783, 21.544, 166.81, 1291.55, 10000.0]

Supplementary table 3 – Tripod checklist, the page columns states the page where the information can be found. appx: appendix, suppl: supplementary

Section/Topic	Item	Checklist Item	Page
Title and abstract			
Title	1	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	1
Abstract	2	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	2
Introduction			
Background and objectives	3a	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	3
	3b	Specify the objectives, including whether the study describes the development or validation of the model or both.	3, 4
Methods			
Source of data	4a	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	5
	4b	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	5
Participants	5a	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	5
	5b	Describe eligibility criteria for participants.	5
	5c	Give details of treatments received, if relevant.	n/a
Outcome	6a	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	5, 6
	6b	Report any actions to blind assessment of the outcome to be predicted.	n/a
Predictors	7a	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	6, table 2, suppl table 1, suppl table 4
	7b	Report any actions to blind assessment of predictors for the outcome and other predictors.	n/a
Sample size	8	Explain how the study size was arrived at.	5

Missing data	9	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	7
Statistical analysis methods	10c	For validation, describe how the predictions were calculated.	7, figure 1
	10d	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	8
	10e	Describe any model updating (e.g., recalibration) arising from the validation, if done.	n/a
Risk groups	11	Provide details on how risk groups were created, if done.	n/a
Development vs. validation	12	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	7, 8
Results			
Participants	13a	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	9
	13b	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	10, Table 1
	13c	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	Table 1
Model performance	16	Report performance measures (with CIs) for the prediction model.	11, 12, 13, table 1, table 2, table 3, Figure 1, suppl table 4
Model-updating	17	If done, report the results from any model updating (i.e., model specification, model performance).	n/a
Discussion			
Limitations	18	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	17
Interpretation	19a	For validation, discuss the results with reference to performance in the development data, and any other validation data.	17
	19b	Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.	19
Implications	20	Discuss the potential clinical use of the model and implications for future research.	18
Other information			
Supplementary information	21	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	appx

Funding	22	Give the source of funding and the role of the funders for the present study.	17
----------------	----	---	----

Supplementary table 4 – Feature set description before and after preprocessing. The average absolute missing, average relative missing, minimum missing per feature and maximum missing per feature are described after preprocessing. The Laboratory & Radiology feature set shows notably higher amount of missing values, likely because no all laboratory values are measured for each patient. In addition, some features were added at a later stage in development, resulting in missing values for patients already included. Note that the difference in features before and after preprocessing includes feature removal and dummification, which occasionally increases the amount of features (see the Clinical Presentation feature set).

Feature set	N features	N Features after preprocessing	Average absolute missing	Average relative missing (%)	Min missing	Max missing
Premorbid	24	22	63	2.8	0	349
Clinical presentation	14	15	92	4.0	0	336
Laboratory & radiology	42	33	490	21.6	0	1023
Premorbid + Clinical presentation	38	37	75	3.3	0	349
All	80	70	271	11.9	0	1023

Supplementary table 5: Performance on internal validation. Performance is evaluated by using 10-fold random subsampling cross-validation. For each metric, the best performance per classifier is highlighted by bold text. LR performed best on all metrics except specificity when trained on the 10 selected features. XGB performed highest using all features on all metrics except negative predictive value. LR: Logistics regression, XGB: Extreme gradient boosting, AUC: Area under de curve, PPV: Positive predictive value, NPV: Negative predictive value

Classifiers	Featureset	AUC	Sensitivity	Specificity	PPV	NPV
LR	Premorbid	0.76 (0.75-0.77)	0.75 (0.73-0.78)	0.67 (0.65-0.70)	0.40 (0.38-0.42)	0.90 (0.90-0.91)
	Clinical Presentation	0.68 (0.65-0.71)	0.59 (0.50-0.68)	0.67 (0.60-0.74)	0.34 (0.30-0.38)	0.86 (0.85-0.87)
	Laboratory and Radiology	0.67 (0.66-0.69)	0.59 (0.56-0.61)	0.67 (0.64-0.71)	0.34 (0.32-0.36)	0.85 (0.84-0.86)
	Premorbid + Clinical Presentation	0.78 (0.77-0.79)	0.73 (0.66-0.79)	0.72 (0.68-0.76)	0.42 (0.39-0.46)	0.90 (0.89-0.92)
	All	0.59 (0.55-0.64)	0.29 (0.14-0.44)	0.83 (0.75-0.92)	0.35 (0.31-0.38)	0.80 (0.77-0.83)
	10 best	0.81 (0.80-0.82)	0.79 (0.77-0.80)	0.71 (0.69-0.73)	0.44 (0.42-0.47)	0.92 (0.91-0.93)
XGB	Premorbid	0.77 (0.76-0.79)	0.78 (0.75-0.81)	0.68 (0.66-0.70)	0.39 (0.37-0.42)	0.68 (0.44-0.92)
	Clinical Presentation	0.73 (0.72-0.74)	0.69 (0.67-0.72)	0.66 (0.64-0.68)	0.37 (0.36-0.39)	0.89 (0.87-0.92)
	Laboratory and Radiology	0.73 (0.71-0.74)	0.70 (0.67-0.72)	0.63 (0.60-0.66)	0.35 (0.33-0.38)	0.88 (0.84-0.92)
	Premorbid + Clinical Presentation	0.81 (0.80-0.82)	0.77 (0.75-0.79)	0.71 (0.70-0.73)	0.45 (0.43-0.47)	0.81 (0.62-1.00)
	All	0.83 (0.81-0.84)	0.78 (0.75-0.80)	0.74 (0.72-0.77)	0.47 (0.45-0.49)	0.91 (0.88-0.95)
	10 best	0.81 (0.80-0.82)	0.75 (0.72-0.77)	0.74 (0.71-0.76)	0.46 (0.43-0.49)	0.91 (0.88-0.94)

Supplementary figure 1 – Pearson correlation matrix of all features. No troublesome collinearity was seen.

